

# Agnese Miro

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3475564/publications.pdf>

Version: 2024-02-01

44  
papers

1,999  
citations

218677

26  
h-index

243625

44  
g-index

45  
all docs

45  
docs citations

45  
times ranked

3121  
citing authors

#	ARTICLE	IF	CITATIONS
1	Alcohol-Based Hand Sanitizers: Does Gelling Agent Really Matter?. <i>Gels</i> , 2022, 8, 87.	4.5	5
2	Hybrid Lipid/Polymer Nanoparticles to Tackle the Cystic Fibrosis Mucus Barrier in siRNA Delivery to the Lungs: Does PEGylation Make the Difference?. <i>ACS Applied Materials &amp; Interfaces</i> , 2022, 14, 7565-7578.	8.0	37
3	Development of a Wet-Granulated Sourdough Multiple Starter for Direct Use. <i>Foods</i> , 2022, 11, 1278.	4.3	3
4	PEGylated mucus-penetrating nanocrystals for lung delivery of a new FtsZ inhibitor against <i>Burkholderia cenocepacia</i> infection. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 23, 102113.	3.3	32
5	Mucoadhesive zein/beta-cyclodextrin nanoparticles for the buccal delivery of curcumin. <i>International Journal of Pharmaceutics</i> , 2020, 586, 119587.	5.2	30
6	Zein Beta-Cyclodextrin Micropowders for Iron Bisglycinate Delivery. <i>Pharmaceutics</i> , 2020, 12, 60.	4.5	4
7	Antimicrobial peptide Temporin-L complexed with anionic cyclodextrins results in a potent and safe agent against sessile bacteria. <i>International Journal of Pharmaceutics</i> , 2020, 584, 119437.	5.2	19
8	Improving in vivo conversion of oleuropein into hydroxytyrosol by oral granules containing probiotic <i>Lactobacillus plantarum</i> 299v and an <i>Olea europaea</i> standardized extract. <i>International Journal of Pharmaceutics</i> , 2018, 543, 73-82.	5.2	20
9	Hybrid Lipid/Polymer Nanoparticles for Pulmonary Delivery of siRNA: Development and Fate Upon <i>In Vitro</i> Deposition on the Human Epithelial Airway Barrier. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2018, 31, 170-181.	1.4	52
10	Poly(ethylene oxide)/hydroxypropyl- $\beta$ -cyclodextrin films for oromucosal delivery of hydrophilic drugs. <i>International Journal of Pharmaceutics</i> , 2017, 531, 606-613.	5.2	8
11	Ultrasmall silver nanoparticles loaded in alginate-hyaluronic acid hybrid hydrogels for treating infected wounds. <i>International Journal of Polymeric Materials and Polymeric Biomaterials</i> , 2017, 66, 626-634.	3.4	33
12	Large Porous Particles for Sustained Release of a Decoy Oligonucleotide and Poly(ethylenimine): Potential for Combined Therapy of Chronic <i>Pseudomonas aeruginosa</i> Lung Infections. <i>Biomacromolecules</i> , 2016, 17, 1561-1571.	5.4	15
13	Nanoassemblies based on non-ionic amphiphilic cyclodextrin hosting Zn(II)-phthalocyanine and docetaxel: Design, physicochemical properties and intracellular effects. <i>Colloids and Surfaces B: Biointerfaces</i> , 2016, 146, 590-597.	5.0	37
14	Polymeric Nanoparticles for Cancer Photodynamic Therapy. <i>Topics in Current Chemistry</i> , 2016, 370, 61-112.	4.0	38
15	Skin transport of PEGylated poly( $\mu$ -caprolactone) nanoparticles assisted by (2-hydroxypropyl)- $\beta$ -cyclodextrin. <i>Journal of Colloid and Interface Science</i> , 2015, 454, 112-120.	9.4	27
16	Toward Repositioning Niclosamide for Antivirulence Therapy of <i>Pseudomonas aeruginosa</i> Lung Infections: Development of Inhalable Formulations through Nanosuspension Technology. <i>Molecular Pharmaceutics</i> , 2015, 12, 2604-2617.	4.6	64
17	Overcoming barriers in <i>Pseudomonas aeruginosa</i> lung infections: Engineered nanoparticles for local delivery of a cationic antimicrobial peptide. <i>Colloids and Surfaces B: Biointerfaces</i> , 2015, 135, 717-725.	5.0	120
18	Pulmonary Drug Delivery: A Role for Polymeric Nanoparticles?. <i>Current Topics in Medicinal Chemistry</i> , 2015, 15, 386-400.	2.1	35

#	ARTICLE	IF	CITATIONS
19	Î²-Cyclodextrin Nanosponges as Multifunctional Ingredient in Water-Containing Semisolid Formulations for Skin Delivery. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 3941-3949.	3.3	34
20	Nanoassembly of an amphiphilic cyclodextrin and Zn(II)-phthalocyanine with the potential for photodynamic therapy of cancer. <i>RSC Advances</i> , 2014, 4, 43903-43911.	3.6	39
21	Core-shell nanocarriers for cancer therapy. Part I: biologically oriented design rules. <i>Expert Opinion on Drug Delivery</i> , 2014, 11, 283-297.	5.0	21
22	Improving the efficacy of inhaled drugs in cystic fibrosis: Challenges and emerging drug delivery strategies. <i>Advanced Drug Delivery Reviews</i> , 2014, 75, 92-111.	13.7	101
23	PEGylated Polyester-Based Nanoncologics. <i>Current Topics in Medicinal Chemistry</i> , 2014, 14, 1097-1114.	2.1	20
24	Engineering poly(ethylene oxide) buccal films with cyclodextrin: A novel role for an old excipient?. <i>International Journal of Pharmaceutics</i> , 2013, 452, 283-291.	5.2	35
25	Engineered PLGA nano- and micro-carriers for pulmonary delivery: challenges and promises. <i>Journal of Pharmacy and Pharmacology</i> , 2012, 64, 1217-1235.	2.4	154
26	Triamcinolone solubilization by (2-hydroxypropyl)-Î²-cyclodextrin: A spectroscopic and computational approach. <i>Carbohydrate Polymers</i> , 2012, 90, 1288-1298.	10.2	12
27	PEI-Engineered Respirable Particles Delivering a Decoy Oligonucleotide to NF-Î²B: Inhibiting MUC2 Expression in LPS-Stimulated Airway Epithelial Cells. <i>PLoS ONE</i> , 2012, 7, e46457.	2.5	11
28	Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: Modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. <i>Journal of Controlled Release</i> , 2012, 157, 149-159.	9.9	240
29	Use of cyclodextrins as solubilizing agents for simvastatin: Effect of hydroxypropyl-Î²-cyclodextrin on lactone/hydroxyacid aqueous equilibrium. <i>International Journal of Pharmaceutics</i> , 2011, 404, 49-56.	5.2	25
30	Engineering gas-foamed large porous particles for efficient local delivery of macromolecules to the lung. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 41, 60-70.	4.0	55
31	Etodolac/cyclodextrin formulations: physicochemical characterization and in vivo pharmacological studies. <i>Drug Development and Industrial Pharmacy</i> , 2009, 35, 877-886.	2.0	9
32	Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: In vivo deposition and hypoglycaemic activity after delivery to rat lungs. <i>Journal of Controlled Release</i> , 2009, 135, 25-34.	9.9	158
33	Modulation of release rate and barrier transport of Diclofenac incorporated in hydrophilic matrices: Role of cyclodextrins and implications in oral drug delivery. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2009, 72, 76-82.	4.3	27
34	Compositions for health products obtained by treatment of tomato with beta-cyclodextrin. <i>Journal of Inclusion Phenomena and Macrocyclic Chemistry</i> , 2007, 57, 669-674.	1.6	1
35	Combined effect of hydroxypropyl methylcellulose and hydroxypropyl-Î²-cyclodextrin on physicochemical and dissolution properties of celecoxib. <i>Journal of Inclusion Phenomena and Macrocyclic Chemistry</i> , 2007, 59, 237-244.	1.6	10
36	Cyclodextrin-containing poly(ethyleneoxide) tablets for the delivery of poorly soluble drugs: Potential as buccal delivery system. <i>International Journal of Pharmaceutics</i> , 2006, 319, 63-70.	5.2	48

#	ARTICLE	IF	CITATIONS
37	Improvement of Solubility and Stability of Valsartan by Hydroxypropyl- $\beta$ -Cyclodextrin. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2006, 54, 289-294.	1.6	61
38	Cyclodextrins in the production of large porous particles: Development of dry powders for the sustained release of insulin to the lungs. European Journal of Pharmaceutical Sciences, 2006, 28, 423-432.	4.0	118
39	Drug/Cyclodextrin Solid Systems in the Design of Hydrophilic Matrices: A Strategy to Modulate Drug Delivery Rate. Current Drug Delivery, 2006, 3, 373-378.	1.6	19
40	Diclofenac $\beta$ -Cyclodextrin Binary Systems: A Study in Solution and in the Solid State. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2003, 46, 179-185.	1.6	21
41	Spectrophotometric determination of polyethylenimine in the presence of an oligonucleotide for the characterization of controlled release formulations. Journal of Pharmaceutical and Biomedical Analysis, 2003, 31, 143-149.	2.8	93
42	Formulation and Preliminary in vivo Testing of Rufloxacin-Cyclodextrin Ophthalmic Solutions. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2002, 44, 173-176.	1.6	10
43	Modulation of drug release from hydrogels by using cyclodextrins: the case of nicardipine/ $\beta$ -cyclodextrin system in crosslinked polyethyleneglycol. Journal of Controlled Release, 2001, 71, 329-337.	9.9	53
44	Chromatographic indexes on immobilized artificial membranes for the prediction of transdermal transport of drugs. Il Farmaco, 1998, 53, 655-661.	0.9	45